Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial.
Ghanbari S, Gohari S, Reshadmanesh T, Mahjani M, Arsang-Jang S, Ismail-Beigi F, Dadashi M, Chiti H, Asgari A, Taheri H, Zolfkhani O, Ahangar H. Ghanbari S, et al. Among authors: mahjani m. J Diabetes Metab Disord. 2024 Mar 7;23(1):1107-1111. doi: 10.1007/s40200-024-01393-8. eCollection 2024 Jun. J Diabetes Metab Disord. 2024. PMID: 38932825
Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial.
Taheri H, Chiti H, Reshadmanesh T, Gohari S, Jalilvand A, Arsang-Jang S, Ismail-Beigi F, Ghanbari S, Dadashi M, Asgari A, Mahjani M, Karbalaee-Hasani A, Ahangar H. Taheri H, et al. Among authors: mahjani m. J Diabetes Metab Disord. 2023 Sep 22;22(2):1723-1730. doi: 10.1007/s40200-023-01305-2. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975102 Free PMC article.
The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial.
Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, Ismail-Beigi F, Dadashi M, Ghanbari S, Taheri H, Fathi M, Muhammadi MJ, Mahmoodian R, Asgari A, Tayaranian M, Moharrami M, Mahjani M, Ghobadian B, Chiti H, Gohari S. Gohari S, et al. Among authors: mahjani m. Diabetol Metab Syndr. 2022 Nov 17;14(1):170. doi: 10.1186/s13098-022-00951-5. Diabetol Metab Syndr. 2022. PMID: 36397128 Free PMC article.
15 results